A Note to Members from Alan Brown, President of the NLA
The National Lipid Association has been quite busy since the 2018 Scientific Sessions in Las Vegas. Below are some of the highlights of the last month. Stay tuned for more recurring updates from our organization.
Guidelines Dissemination Task Force
With the anticipated November 2018 release of the 2018 Guideline on the Management of Blood Cholesterol, the NLA is determined to participate actively in the dissemination of the update. As a result, I have developed a Guidelines Dissemination Task Force, chaired by Karen E. Aspry, MD, MS, FNLA.
The Task Force met for the first time on Friday, June 15 to start the process of preparing for the release of the updated cholesterol guidelines. The Task Force will focus its work on collaborations with the American College of Cardiology and American Heart Association, necessary updates to existing NLA content, and internal and external messaging.
As you know, the NLA is participating as an official partner organization in the development of the 2018 cholesterol guidelines. Carl E. Orringer, MD, FNLA is the NLA representative. The NLA Board of Directors will have the opportunity to endorse the guidelines prior to its release in November.
ISA Participation & IAS Collaboration
Congratulations to Scott Heximer, PhD and Robert Hegele, MD for their efforts in hosting the XVIII International Symposium on Atherosclerosis in Toronto. With their support and the support of the International Atherosclerosis Society, the NLA had a superb presence at the meeting.
During the opening session, the NLA and Foundation of the NLA awarded the Akira Endo Award for Achievements in the Development of Treatments to Prevent Atherosclerosis to Jonathan C. Cohen, PhD, and Nabil G. Seidah, PhD. Thank you to W. Virgil Brown, MD, FNLA, Ernst J. Schaefer, MD, FNLA and James A. Underberg, MD, MS, FNLA for their participation.
The NLA also hosted a symposium entitled, “Bridging the Gaps in Treatment of Genetic Triglyceride Disorders: A Team-Based Approach to Differential Diagnoses and Management” on June 11 during the ISA meeting. Chantal Blais, Dt.P, Joseph J. Saseen, PharmD, CLS, FNLA, James A. Underberg, MD, MS, FNLA, and I participated as faculty.
Finally, I had a chance to meet with Raul D. Santos, MD, PhD, President of the International Atherosclerosis Society about opportunities to collaborate between NLA and IAS. NLA is a constituent society of IAS, and both organizations have much to offer the other. Dr. Santos and I will continue the discussion on collaborative opportunities, and I will present our discussions at the next NLA Board of Directors meeting.
Type 2 Diabetes Expert Consensus Pathway Review Request
The American College of Cardiology requested a peer review by the NLA of the 2018 Type 2 Diabetes Expert Consensus Decision Pathway. I have asked James M. Falko, MD, FNLA to review the document on behalf of the organization and submit commentary to the ACC.
South Asian Work Group
I am thrilled to announce the development of the NLA’s South Asian Working Group. The working group will focus on development of content specific to the effective treatment of the South Asian population, taking special consideration of the NLA Recommendations Part II. The first meeting of the South Asian Workgroup was June 27.
AHA's Check. Change. Control. Cholesterol Campaign
The American Heart Association has developed a campaign called Check. Change. Control. Cholesterol, that aims to achieve better cholesterol management (target groups identified in the 2013 AHA/ACC Guidelines that are most likely to benefit from statin therapy) by promoting the CCCC initiative and ASCVD calculator implementation at health centers across Western States Affiliate. The goal of CCCC is to encourage and support providers to ensure at least 70% of adult, at-risk ASCVD patients are appropriately managed with statin therapy by December 31, 2019.
The Pacific Lipid Association is working on a pilot collaboration with the Western States Affiliate of AHA, which includes Arizona, Alaska, California, Hawaii, Idaho, Montana, Nevada, Oregon, Utah and Washington, to implement the CCCC campaign. I look forward to hearing from our PLA colleagues on the execution of this initiative.
Fall CLU Information
I hope everyone plans on joining us in Nashville for the Fall Clinical Lipid Update which is scheduled for September 21-23 at the Loews Vanderbilt Hotel. The meeting features a wonderful faculty and topics including:
• Defining Targets, Goals and Thresholds for Treatment
• Back to Basics: Lifestyle Strategies in the Management of Dyslipidemia
• Emerging Science in Clinical Lipidology
• Lipoprotein(a): The Neglected CVD Risk Factor
• NLA Special Session – Bridging the Gaps in Treatment of Genetic Triglyceride Disorders: A Team-Based Approach to Differential Diagnoses and Management
• Complex Cases with the "Aces"
• Plaque Biology and Implications for Clinical Practice
The meeting also features the Foundations of Lipidology and Masters in Lipidology courses. For more information and to register, visit lipid.org/fallclu. Early bird prices end July 27, and hotel rooms are filling up fast, so do not delay.
Remember, we need everyone to proudly wave the NLA flag! As always, please feel free to contact me at: firstname.lastname@example.org with any comments or questions.
Alan S. Brown, MD, FNLA
President, National Lipid Association
Director, Division of Cardiology
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL